Otto, Angela M. and Bednarski, Patrick J. and Eggers, Hella and Truembach, Barbara and Schönenberger, Helmut (1992) [Meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)enthylenediamine] dichloroplatinum(II), an estrogenic platinum(II)-complex for the therapy of breast cancer: relationship between stability and effect. Pharmaceutical and pharmacological letters 1 (3), pp. 103-106.
Full text not available from this repository.
The inhibiting effect of [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]dichloroplatinum(II) (meso-Pt(1)Cl2) (I) on the estrogen receptor-pos. (ER+) breast cancer in vivo is due to its cytotoxic as well as its estrogenic properties. In in vitro expts. on the ER+ MCF-7 breast cancer cell line meso-Pt(1)Cl2 can react with bionucleophils in cell culture medium, esp. with serum proteins, which leads to the release of the pharmacol. active diammine ligand. The comparison of the kinetics of ligand release with the exposure time required for meso-Pt(1)Cl2 to induce its cytotoxic and estrogenic effects (i.e. induction of ER-processing and progesterone receptor synthesis) show that the biol. response of the MCF-7 cells can be attributed to the intact meso-Pt(1)Cl2.
|Additional information (public):||CAN 117:204657 1-6 Pharmacology 105856-23-3 Role: BIOL (Biological study) (breast cancer inhibition by)|
|Institutions:||Chemistry and Pharmacy > Institute of Pharmacy > Retired Professors > Prof. Schönenberger|
|Keywords:||Neoplasm inhibitors (mammary gland, estrogenic platinum(II) complex as) Mammary gland (neoplasm, inhibitors, estrogenic platinum(II) complex as) estrogenic platinum complex breast cancer inhibitor|
|Subjects:||500 Science > 540 Chemistry & allied sciences|
|Refereed:||Yes, this version has been refereed|
|Created at the University of Regensburg:||Yes|
|Deposited On:||12 Nov 2010 06:56|
|Last Modified:||12 Nov 2010 06:56|